Tradestie Institutional Equity Comparison Engine

ZBIO vs CHAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Growth & Margin, Options & Structure while CHAD counters with relative strength in Momentum & Technical. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus CHAD at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against CHAD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs CHAD N/M Fwd P/E
Growth & Margin Winner ZBIO
Op Margin -2747.5% vs N/A ยท YoY -100.0% vs N/A
Momentum & Technical Winner CHAD
1Y -21.7% vs +19.6% ยท 52W Pos 46% vs 100%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
CHAD US Equity
CHAD
Institutional Equity
$10.00
+0.21% 1D
Market Cap N/A
1M Return +7.07%
1Y Return +19.62%
Forward P/E N/M
Unified AI Score
53.8 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% CHAD +19.62% Spread: +35.11 pp (CHAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZBIO TTM Op. Margin: -2747.5% CHAD TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs CHAD. Trailing 12-month operating profitability (ZBIO -2747.5% vs CHAD N/A) and valuation multiples (ZBIO N/M vs CHAD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (5) vs CHAD (3)
Institutional Metric ZBIO CHAD Criterion Row Winner
Market Capitalization Scale $1.9B N/A Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% N/A Higher Growth ZBIO
Operating Margin (TTM) Profitability -2747.5% N/A Higher Margin ZBIO
Net Profit Margin Profitability 0.0% N/A Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -265.1% N/A Higher ROE ZBIO
52-Week Range Position Momentum 46% ($14โ€“$45) 100% ($7โ€“$10) Stronger Trend CHAD
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 0.71ฮฒ ยท 11% Vol Lower Realized Risk CHAD
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 53.8 / 100 (HOLD) Higher Composite CHAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs CHAD Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CHAD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CHAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor CHAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.